Bionano Genomics Inc. [NASDAQ: BNGO] traded at a low on 05/28/21, posting a -0.80 loss after which it closed the day’ session at $6.17. The company report on May 20, 2021 that Bionano Genomics to Present at the 2021 Oppenheimer MedTech, Tools & Diagnostic Summit.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced that company management will present virtually at the Oppenheimer MedTech, Tools & Diagnostics Summit being held on May 26, 2021.
The presentation will be available to view on the Events page in the Investors section of Bionano’s website and at Oppenheimer MedTech, Tools, & Diagnostics Summit (wsw.com) on May 26, 2021 at 8am ET. The webcast of the event will be archived on Bionano’s website for 30 days following the event.
The results of the trading session contributed to over 12796792 shares changing hands. Over the past one week, the price volatility of Bionano Genomics Inc. stands at 7.87% while the volatility over the past one month is 9.35%.
The market cap for BNGO stock reached $1.73 billion, with 278.79 million shares outstanding and 276.45 million shares in the current float. Compared to the average trading volume of 25.24M shares, BNGO reached a trading volume of 12796792 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Bionano Genomics Inc. [BNGO]?
Ladenburg Thalmann have made an estimate for Bionano Genomics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 24, 2020. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on April 08, 2020, representing the official price target for Bionano Genomics Inc. stock.
The Average True Range (ATR) for Bionano Genomics Inc. is set at 0.56, with the Price to Sales ratio for BNGO stock in the period of the last 12 months amounting to 165.18. The Price to Book ratio for the last quarter was 4.50, with the Price to Cash per share for the same quarter was set at 1.29.
How has BNGO stock performed recently?
Bionano Genomics Inc. [BNGO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.78. With this latest performance, BNGO shares dropped by -6.66% in over the last four-week period, additionally plugging by 1161.76% over the last 6 months – not to mention a rise of 1274.16% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNGO stock in for the last two-week period is set at 53.39, with the RSI for the last a single of trading hit 60.85, and the three-weeks RSI is set at 49.73 for Bionano Genomics Inc. [BNGO]. The present Moving Average for the last 50 days of trading for this stock 6.48, while it was recorded at 5.87 for the last single week of trading, and 4.43 for the last 200 days.
Bionano Genomics Inc. [BNGO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Bionano Genomics Inc. [BNGO] shares currently have an operating margin of -435.74 and a Gross Margin at +21.67. Bionano Genomics Inc.’s Net Margin is presently recorded at -483.43.
Return on Total Capital for BNGO is now -98.66, given the latest momentum, and Return on Invested Capital for the company is -149.42. Return on Equity for this stock declined to -212.46, with Return on Assets sitting at -90.69. When it comes to the capital structure of this company, Bionano Genomics Inc. [BNGO] has a Total Debt to Total Equity ratio set at 46.54. Additionally, BNGO Total Debt to Total Capital is recorded at 31.76, with Total Debt to Total Assets ending up at 27.01. Long-Term Debt to Equity for the company is recorded at 46.54, with the Long-Term Debt to Total Capital now at 31.76.
Reflecting on the efficiency of the workforce at the company, Bionano Genomics Inc. [BNGO] managed to generate an average of -$279,635 per employee. Receivables Turnover for the company is 1.87 with a Total Asset Turnover recorded at a value of 0.19.Bionano Genomics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 51.20 and a Current Ratio set at 51.60.
Earnings analysis for Bionano Genomics Inc. [BNGO]
With the latest financial reports released by the company, Bionano Genomics Inc. posted -0.09/share EPS, while the average EPS was predicted by analysts to be reported at -0.09/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BNGO.
Insider trade positions for Bionano Genomics Inc. [BNGO]
There are presently around $267 million, or 15.50% of BNGO stock, in the hands of institutional investors. The top three institutional holders of BNGO stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 9,486,494, which is approximately New of the company’s market cap and around 0.30% of the total institutional ownership; VANGUARD GROUP INC, holding 9,295,839 shares of the stock with an approximate value of $57.35 million in BNGO stocks shares; and INVESCO LTD., currently with $25.87 million in BNGO stock with ownership of nearly New of the company’s market capitalization.
Positions in Bionano Genomics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 112 institutional holders increased their position in Bionano Genomics Inc. [NASDAQ:BNGO] by around 32,171,198 shares. Additionally, 17 investors decreased positions by around 1,434,823 shares, while 2 investors held positions by with 9,616,434 shares. The mentioned changes placed institutional holdings at 43,222,455 shares, according to the latest SEC report filing. BNGO stock had 84 new institutional investments in for a total of 20,000,393 shares, while 12 institutional investors sold positions of 318,575 shares during the same period.